Business Wire

Results from Pradaxa® RE-SPECT ESUS® and RE-SPECT CVT® trials to be presented at the 11th World Stroke Congress

Jaa

Boehringer Ingelheim today announced that primary results from two key trials, RE-SPECT ESUS® and RE-SPECT CVT®, will be presented at the upcoming World Stroke Congress in Montreal, Canada 17-20 October 2018. These primary analyses will contribute to the scientific community’s understanding of both disease states and the clinical profile of dabigatran etexilate (Pradaxa®).

The results from RE-SPECT ESUS, the first randomised trial comparing dabigatran etexilate with acetylsalicylic acid (ASA) in any indication, will add further insight into the prevention of secondary stroke in patients with an embolic stroke of undetermined source (ESUS).1 As the first comparison to ASA, this trial will also offer further important insights into the clinical profile of dabigatran etexilate.

RE-SPECT CVT will provide additional knowledge regarding treatment of patients with cerebral venous thrombosis (CVT).2 It is the first exploratory, prospective, randomised controlled study of any non-vitamin K antagonist oral anticoagulant (NOAC) in patients with blood clots in the veins or venous sinuses of the brain.

Both trials are part of Boehringer Ingelheim’s ongoing commitment to expanding scientific knowledge of stroke prevention and form part of the extensive RE-VOLUTION® clinical trial programme for dabigatran etexilate, which upon completion will have enrolled more than 60,000 patients worldwide.1-14

The results from these two trials will be presented in the following sessions:

Abstract title   Presentation details
RE-SPECT ESUS: Dabigatran versus acetylsalicylic acid for stroke prevention in patients with embolic stroke of undetermined source Wednesday 17 October, 19:10 – 19:30, HALL A

Session code: AWA01

Session title: Opening: late-breaking trials

Presentation number: 100

RE-SPECT CVT: Randomized controlled trial of the safety and efficacy of dabigatran etexilate vs. dose-adjusted warfarin in patients with cerebral venous thrombosis Saturday 20 October, 11:30 – 11:50, HALL B

Session code: AWA03

Session title: Award lectures & late breaking trials

Presentation number: 101

Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/Results-from-two-Pradaxa-trials-to-be-presented-at-WSC

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. It is directed to the international audience outside Germany. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Contact information

Boehringer Ingelheim
Corporate Communications
Media + PR
Meike Bausinger
Phone: +49 6132 77 182085
Mobile: +49 151 44061760
Fax: +49 6132 77 6601
Email: press@boehringer-ingelheim.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease21.1.2019 12:00Tiedote

Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for ORKAMBI® (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) aged 2 to 5 years old who have two copies of the F508del mutation, the most common form of the disease. “Today’s approval by the European Commission brings us one step closer to our goal of bringing treatment to all people living with CF,” said Reshma Kewalramani, MD, Executive Vice President, Global Medicines Development and Medical Affairs and Chief Medical Officer at Vertex. ‘‘By treating the underlying cause of disease early, we can potentially modify its course and offer patients the chance of improved outcomes.’’ The label update is based on data from a Phase 3 open-label safety study in 60 patients that showed treatment with lumacaftor/ivacaftor was generally well tolerated for 24 weeks, with a safety profile in these pediatric patients generally consistent with

Anticipation Builds as MWC19 Barcelona Approaches21.1.2019 12:00Tiedote

The GSMA today announced final updates for MWC19 Barcelona (formerly Mobile World Congress), including additional keynote speakers, participating companies, programmes and events. Taking place 25-28 February 2019, with events being staged at Fira Gran Via, Fira Montjuïc and La Farga L’Hospitalet, MWC19 Barcelona is set to attract more than 107,000 professionals from over 200 countries and territories. “With the anticipated arrival of 5G, this year’s event is set to be one of the most exciting as the industry convenes to showcase Intelligent Connectivity across new technologies on the brink of reaching millions of people across the world,” said John Hoffman, CEO, GSMA Ltd. “Over the four days of MWC19, attendees will have the opportunity to hear from leaders who are driving innovation and we look forward once again to welcoming the mobile world to Barcelona.” Global Leaders to Keynote The GSMA announced the addition of several new keynote speakers for MWC19 including executives from lea

B2C2 Launches Streaming OTC Pricing with Point-and-Click Execution21.1.2019 12:00Tiedote

B2C2, one of the largest cryptocurrency liquidity providers and the leader in electronic OTC trading, today announced the launch of streaming pricing with point-and-click execution on its OTC platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005063/en/ Max Boonen, Founder and CEO of B2C2 (Photo: Business Wire) For the first time, B2C2’s clients will be able to view and execute trades on a real-time two-way market, via the firm’s secure web interface. The new functionality allows market participants to easily monitor live pricing in user-defined quantities and execute with the click of a button, as they would on traditional FX trading platforms. The launch rounds out a number of milestones for B2C2 in 2018, including surpassing 2017 peak volumes; rolling out a completely redesigned front-end; forming integration partnerships with the major liquidity hubs; and launching a research offering. Founded in 2015, B2C2 i

Alnylam Pharmaceuticals and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel21.1.2019 11:00Tiedote

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma, Israel’s leading commercial partner for innovative pharmaceuticals, announced today an exclusive agreement to commercialize ONPATTRO®, the first-ever commercialized RNAi therapeutic, as well as other investigational therapeutics under development in the Alnylam RNAi portfolio. “Our partnership with Medison marks an important step in our global commercial expansion and signals our intent to ensure that patients suffering from serious rare diseases have access to our medicines, regardless of location,” said Theresa Heggie, SVP and Head of Europe, Middle East and Africa, and Canada, Alnylam Pharmaceuticals. “Medison has a strong organization with a proven track record of commercializing orphan products successfully, together with an infrastructure uniquely suited to supporting patients suffering from rare diseases in Israel and providing access to our potentially transformational thera

Gore Introduces GORE® TAG® Conformable Thoracic Stent Graft with Reduced Profiles in Europe21.1.2019 11:00Tiedote

W. L. Gore & Associates, Inc. (Gore) today introduced reduced profiles for the most commonly used diameters of the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System. The reduced profile allows physicians to perform TEVAR in patients with smaller vessels where access is challenging and aortic anatomy is tortuous, expanding the availability of Gore’s thoracic stent graft to a greater population of patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005042/en/ GORE(R) TAG(R) Conformable Thoracic Stent Graft with ACTIVE CONTROL System (Photo: Business Wire) The GORE® TAG® Conformable Thoracic Stent Graft was modified to reduce the delivery profile of the 31, 37, and 40 mm device diameters by 2 Fr for all lengths. The reduction in profile, through the use of a smaller diameter primary sleeve, is the only change to the device. The stent graft leverages the same predictable outcomes of the time-teste

HCL 2030 Ecosystem Platform to Explore Societal Implications of Emerging Technology at the World Economic Forum21.1.2019 10:26Tiedote

HCL Technologies (HCL), a leading global technology company and the World Economic Forum’s Strategic Partner, today announced its largest presence to date at the side-lines of World Economic Forum’s Annual Meeting in Davos scheduled from 21st January 2019 to 25th January 2019. The company will host a three-day event in a special Pavilion that will feature a technology showcase, thought-leadership programs, as well as a number of high-level networking and social events throughout the tenure of the conference. The overarching theme of the HCL and Fast Company programs will explore how humanity’s relationship with technology will evolve through the next decade of rapid innovation. HCL has partnered with Fast Company to develop a thought-leadership track that includes three panel discussion breakfasts. As part of the theme of Human-Machine Harmony, HCL is launching the HCL 2030 Platform, together with its ecosystem of partners and stakeholders, that will conduct in-depth explorations and d

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme